|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn646758662 |
003 |
OCoLC |
005 |
20231117033250.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
081212s1994 caua ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d OCLCQ
|d UBY
|d N$T
|d IDEBK
|d OCLCQ
|d OPELS
|d OCLCQ
|d OCLCF
|d OCLCO
|d OCLCQ
|d DEBSZ
|d LEAUB
|d VLY
|d OCLCO
|d COM
|d OCLCO
|d INARC
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 373496184
|a 505079389
|a 1162049481
|
020 |
|
|
|a 9780080583730
|q (electronic bk.)
|
020 |
|
|
|a 0080583733
|q (electronic bk.)
|
020 |
|
|
|a 0120405296
|q (electronic bk.)
|
020 |
|
|
|a 9780120405299
|q (electronic bk.)
|
020 |
|
|
|a 1281739901
|
020 |
|
|
|a 9781281739902
|
020 |
|
|
|a 9786611739904
|
020 |
|
|
|a 6611739904
|
035 |
|
|
|a (OCoLC)646758662
|z (OCoLC)373496184
|z (OCoLC)505079389
|z (OCoLC)1162049481
|
050 |
|
4 |
|a RS402
|b .A6529 1994eb
|
072 |
|
7 |
|a MED
|x 023000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 058170
|2 bisacsh
|
082 |
0 |
4 |
|a 615./19
|2 22
|
245 |
0 |
0 |
|a Annual reports in medicinal chemistry.
|n Volume 29.
|
260 |
|
|
|a San Diego, Calif. ;
|a London :
|b Academic Press,
|c 1994.
|
300 |
|
|
|a 1 online resource (xiii, 397 pages) :
|b illustrations.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
0 |
|
|a Annual reports in medicinal chemistry ;
|v v. 29
|
504 |
|
|
|a Includes bibliographical references and indexes.
|
520 |
|
|
|a This serial continues to combine regular updates of significant research in medicinal chemistry with emerging research in biological science destined to impact the discovery and development of new medicinal agents.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Front Cover; Annual Reports in Medicinal Chemistry, Volume 29; Copyright Page; Contents; Contributors; Preface; SECTION I: CNS AGENTS; Chapter 1. Toward Third Generation Antidepressants; Chapter 2. Neuronal Cell Death and Strategies for Neuroprotection; Chapter 3. Recent Advances in the Design and Characterization of Muscarinic Agonists and Antagonists; Chapter 4. Animal Engineering in Neurobiology; Chapter 5. Recent Advances in Dopamine D3 and D4 Receptor Ligands and Pharmacology; Chapter 6. Recent Progress in Excitatory Amino Acid Resesarch; SECTION II: CARDIOVASCULAR AND PULMONARY AGENTS
|
505 |
8 |
|
|a Chapter 7. Small Molecule Endothelin Receptor AntagonistsChapter 8. Emerging Opportunities in the Treatment of Asthma and Allergy; Chapter 9 . The Enzymology and Manipulation of Nitric Oxide Synthase; Chapter 10. Thrombolytic Agents; Chapter 11. Antithrombotic and Anti-Inflammatory Agents of the Protein C Anticoagulant Pathway; SECTION III: CHEMOTHERAPEUTIC AGENTS; Chapter 12. Antibacterial Agents; Chapter 13. Advances in the Development of HIV Reverse Transcriptase Inhibitors; Chapter 14. HIV Protease Inhibitors; Chapter 15. Antiviral Agents
|
505 |
8 |
|
|a Chapter 16. Problems and Progress in Opportunistic InfectionsChapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy; SECTION IV: IMMUNOLOGY, ENDOCRINOLOGY,AND METABOLIC DISEASES; Chapter 18. Non-lmmunophilin-Related Immunosuppressants; Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents; Chapter 20. Human Leukocyte Elastase Inhibitors; Chapter 21. Interleukin-1 as a Therapeutic Target; Chapter 22. Cell Adhesion and Carbohydrates; Chapter 23. Therapeutic Control of Androgen Action; SECTION V: TOPICS AN BIOLOGY
|
505 |
8 |
|
|a Chapter 24. Transcription Factor NF-KB: An Emerging Regulator of InflammationChapter 25. Translational Control of Gene Expression; Chapter 26. Protein Kinases and Phosphatases: Structural Biology and Synthetic Inhibitors; Chapter 27. Transgenic and Gene Targeting Technology in Drug Discovery; Chapter 28. Emerging Therapies in Osteoporosis; SECTION VI: TOPICS IN DRUG DESIGN AND DESCOVERY; Chapter 29. Adenylate Cyclase Subtypes as Molecular Drug Targets; Chapter 30. Recent Advances in Antisense Technology; Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism
|
505 |
8 |
|
|a Chapter 32. Humanized Monoclonal AntibodiesChapter 33. Ethnobotany as a Source for New Drugs; SECTION VII: TRENDS AND PERSPECTIVES; Chapter 34. To Market, To Market -- 1993; Compound Name, Code Number and Subject Index, Volume 29; Cumulative Chapter Titles Keyword Index, Volumes 1-29; Cumulative Nce Introduction Index, 1983-1993; Cumulative Nce Introduction Index, 1983-1993, by Indication
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Pharmaceutical chemistry
|v Periodicals.
|
650 |
|
0 |
|a Clinical chemistry
|v Periodicals.
|
650 |
|
6 |
|a Chimie pharmaceutique
|0 (CaQQLa)201-0028674
|v P�eriodiques.
|0 (CaQQLa)201-0378307
|
650 |
|
6 |
|a Chimie clinique
|0 (CaQQLa)201-0016714
|v P�eriodiques.
|0 (CaQQLa)201-0378307
|
650 |
|
7 |
|a MEDICAL
|x Drug Guides.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Nursing
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Clinical chemistry
|2 fast
|0 (OCoLC)fst00864330
|
650 |
|
7 |
|a Pharmaceutical chemistry
|2 fast
|0 (OCoLC)fst01060115
|
655 |
|
2 |
|a Periodical
|0 (DNLM)D020492
|
655 |
|
7 |
|a periodicals.
|2 aat
|0 (CStmoGRI)aatgf300026657
|
655 |
|
7 |
|a Periodicals
|2 fast
|0 (OCoLC)fst01411641
|
655 |
|
7 |
|a Periodicals.
|2 lcgft
|
655 |
|
7 |
|a P�eriodiques.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001105
|
700 |
1 |
|
|a Bristol, James A.,
|d 1946-
|
710 |
2 |
|
|a American Chemical Society.
|b Division of Medicinal Chemistry.
|
776 |
0 |
8 |
|i Print version:
|t Annual reports in medicinal chemistry. Volume 29.
|d San Diego : Academic Press, �1994
|z 0120405296
|z 9780120405299
|w (OCoLC)42286450
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780120405299
|z Texto completo
|